Ensuring Access to Medicines in Frame of the Right to Share in Scientific Advancement and its Benefits

Aslan Khuseinovich Abashidze; Vladislav Malichenko

Aslan Khuseinovich Abashidze RUDN University
Vladislav Malichenko The Institute of legislation and comparative law under the Government of the Russian Federation http://orcid.org/0000-0003-3136-8054

Keywords: right to health, access to medicines, patent protection, compulsory licensing, TRIPS

Abstract

A significant role in providing access to medicines is rightfully played by legal norms regulating intellectual property protection. The pharmaceutical sector stands out among other industries in terms of implementation of various mechanisms of intellectual property rights protection, which guarantee the possibility to recover economic losses due to tremendous investments in R&D. However, intellectual property protection mechanisms trigger the rise of medication costs, which significantly influence state expenditures and limit patient’s access to treatment. At the time of scientific achievements access to medicines is directly linked with the right “to enjoy the benefits of scientific progress and its applications”. It means that initiatives implemented by international organizations and national healthcare policies should contain balanced approach between the interests of the society and pharmaceutical producers in order to protect public and private interests.

Downloads

Download data is not yet available.

Author Biographies

Aslan Khuseinovich Abashidze, RUDN University

Professor, Head of Department, RUDN University, Department of International Law, 101001 Moscow, Russian Federation, e-mail: abashidze-akh@rudn.ru

Vladislav Malichenko, The Institute of legislation and comparative law under the Government of the Russian Federation

Senior Researcher, The Institute of legislation and comparative law under the Government of the Russian Federation, Moscow, Russian Federation, e-mail: vlad.malichenko@gmail.com

References

Coriat, B., Orsi, F., d’ Almeida, C. (2006) TRIPS and the international public health controversies: issues and challenges, Industrial and Corporate Change, 15(6), pp. 1033–1062.doi:10.1093/icc/dtl029.

DiMasi, J. A., Grabowski, H. G. (2007) The Cost of Biopharmaceutical R&D: Is Biotech Different?, Managerial and Decision Economics, 28(4–5), pp. 469–479.

DiMasi, J. A., Hansen, R. W., Grabowski, H. G. (2003) The Price of Innovation: New Estimates of Drug Development Costs, Journal of Health Economics 22(2), pp. 151–185.

Ecorys, B. (2009) Competitiveness of the EU market and industry for pharmaceuticals. Volume II: Markets, Innovation & Regulation, European Commission, Directorate General Enterprise & Industry.

Lanjouw J. O., Cockburn, I. (2000) Do patents matter? Empirical evidence after GATT, Working Paper No. 7495, 200032.

Desai, M. A. (2016) Compulsory licensing: Procedural requirements under the TRIPS agreement, Pharmaceuticals Policy and Law, 18, pp. 31–44.

Reed, F. B. (2016) Patents and the WHO Model List of Essential Medicines: Clarifying the Debate on IP and Access, WIPO.

Roffe, P., Spennemann, C. (2006) The impact of FTAs on public health policies and TRIPS flexibilities. International Journal of Intellectual Property Management, 1(1-2), pp. 75–93.

Storz, U. (2012) Patent Lifecycle Management, Supplementary Protection Certificates and Data Exclusivity in Biopharmaceutics, Biopatent Law: Patent Strategies and Patent Management, pp. 25–41.

Taylor, C. T., Silberston, Z. A. (1973) The Economic Impact of the Patent System: A Study of the British Experience (Cambridge, UK: Cambridge University).

Wirtz, V. J. et al. (2017) Essential medicines for universal health coverage – Authors' reply, The Lancet, 389(10082), pp. 1881–1882.

Wu, H. (2006) Fundamental principles of the international protection system of intellectual property rights and the applications, Front. Law China,1, pp. 329–348.